I n a challenging market environment, Alector Inc (NASDAQ:ALEC) stock has touched a 52-week low, sinking to $1.59. With a market capitalization of $158.65 million, InvestingPro analysis suggests ...

April 17, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of ...

Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer role-- "It has been a privilege to work alongside the talented team at Alector to advance a pipeline of therapies designed to ...

(Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...

Alector, Inc. (NASDAQ:ALEC – Free Report) – Stock analysts at Cantor Fitzgerald raised their FY2025 earnings estimates for Alector in a report released on Thursday, February 27th.Cantor ...

I n a challenging market environment, Alector Inc (NASDAQ:ALEC) stock has touched a new 52-week low, with shares plummeting ...

March 28, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer role-- SOUTH SAN FRANCISCO, Calif., March 28, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical ...

March 28, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of ...